| |
|
|
Hypogonadal Not Treated Group |
Hypogonadal Treated Group |
| |
Control Group |
Placebo H–T+P |
Sildenafil H–T+S |
Placebo H+T+P |
Sildenafil H+T+S |
| |
Placebo C+P |
Sildenafil C+S |
|
| Number of valid erections |
3.17 (0.26) |
4.17 (0.27) |
0.76 (0.22) |
2.71 (0.18) |
2.79 (0.27) |
4.29 (0.24) |
| Total duration of rigidity > 70%, min |
60.66 (7.98) |
108.04 (11.43) |
10.57 (3.83) |
43.59 (5.14) |
52.02 (8.74) |
105.48 (13.02) |
Total duration of increase of circumference  30 mm, min |
51.78 (5.84) |
103.49 (10.42) |
6.67 (1.83) |
30.14 (4.26) |
38.63 (5.01) |
100.02 (11.45) |
| Maximum rigidity, % |
89.46 (2.11) |
94.04 (1.39) |
60.83 (3.83) |
79.21 (3.44) |
84.00 (2.10) |
91.75 (1.54) |
| Maximum increase of circumference, mm |
40.50 (1.38) |
44.58 (1.45) |
25.79 (1.45) |
33.46 (0.89) |
40.00 (1.70) |
43.58 (1.31) |
| Number of Valid Erections |
| C+P vs C+S: P < .05 |
C+P vs H–T+S: n.s. |
H–T+P vs H–T+S: P < .0001 |
| C+P vs H+T+S: P < .05 |
C+P vs H+T+P: n.s. |
H–T+P vs H+T+S: P < .0001 |
| C+P vs H–T+P: P < .0001 |
C+S vs H+T+S: n.s. |
H–T+P vs H+T+P: P < .0001 |
| C+S vs H–T+P: P < .0001 |
|
|
H–T+S vs H+T+S: P < .0001 |
| C+S vs H–T+S: P < .0001 |
|
|
H+T+P vs H+T+S: P < .0001 |
| C+S vs H+T+P: P = .001 |
|
|
|
|
|
|
| Total Duration of Rigidity 70%, min |
| C+P vs C+S: P < .005 |
C+P vs H–T+S: n.s. |
H–T+P vs H+T+P: P < .05 |
| C+P vs H+T+S: P = .005 |
C+P vs H+T+P: n.s. |
H–T+P vs H+T+S: P < .0001 |
| C+P vs H–T+P: P = .001 |
C+S vs H+T+S: n.s. |
H–T+S vs H+T+S: P < .0001 |
| C+S vs H–T+P: P < .0001 |
|
|
H–T+P vs H+T+S: P < .0001 |
| C+S vs H–T+S: P < .0001 |
|
|
|
|
|
|
| C+S vs H+T+P: P < .0001 |
|
|
|
|
|
|
| Total Duration of Increase of Circumference 30 mm, min |
| C+P vs C+S: P < .0001 |
C+P vs H–T+S: n.s. |
H–T+P vs H+T+P: P < .05 |
| C+P vs H+T+S: P < .0001 |
C+P vs H+T+P: n.s. |
H–T+P vs H+T+S: P < .0001 |
| C+P vs H–T+P: P < .0001 |
C+S vs H+T+S: n.s. |
H–T+S vs H+T+S: P < .0001 |
| C+S vs H–T+P: P < .0001 |
|
|
H+T+P vs H+T+S: P < .0001 |
| C+S vs H–T+S: P < .0001 |
|
|
|
|
|
|
| C+S vs H+T+P: P < .0001 |
|
|
|
|
|
|
| Maximum Rigidity, % |
| C+P vs H–T+P: P < .0001 |
C+P vs C+S: n.s. |
H–T+P vs H–T+S: P < .0001 |
| C+S vs H–T+P: P < .0001 |
C+P vs H–T+S: n.s. |
H–T+P vs H+T+P: P < .0001 |
| C+S vs H–T+S: P = .0001 |
C+P vs H+T+P: n.s. |
H–T+P vs H+T+S: P < .0001 |
| |
C+P vs H+T+S: n.s. |
H–T+S vs H+T+S: P < .01 |
| |
C+S vs H+T+P: n.s. |
|
|
|
|
| |
C+S vs H+T+S: n.s. |
|
|
|
|
| Maximum Increase of Circumference, mm |
| C+P vs H–T+P: P < .0001 |
C+P vs C+S: n.s. |
H–T+P vs H–T+S: P = .001 |
| C+P vs H–T+S: P < .005 |
C+P vs H+T+P: n.s. |
H–T+P vs H+T+P: P < .0001 |
| C+S vs H–T+P: P < .0001 |
C+P vs H+T+S: n.s. |
H–T+P vs H+T+S: P < .0001 |
| C+S vs H–T+S: P < .0001 |
C+S vs H+T+P: n.s. |
H–T+S vs H+T+P: P < .05 |
| |
C+S vs H+T+S: n.s. |
H–T+S vs H+T+S: P < .0001 |
|
| *The comparisons among groups were performed by means of one-way analysis of
variance, and results are reported above. The level of significance was .05.
All comparisons between control groups and hypogonadal men are reported in the
table, even if they are not significant. For comparisons among hypogonadal
men, only those that were significant are reported, because more detailed and
appropriate statistical analyses have been performed (see the text). NPTRM
indicates nocturnal penile tumescence and rigidity monitoring; n.s., not
significant; C+P, controls taking placebo; C+S, controls taking sildenafil;
H–T+P, hypogonadal men before testosterone treatment taking placebo;
H–T+S, hypogonadal men before testosterone treatment taking sildenafil;
H+T+P, hypogonadal men during testosterone treatment taking placebo; and
H+T+S, hypogonadal men during testosterone treatment taking sildenafil. Both
placebo and sildenafil were taken at bedtime |
